Skip to main content

Demonstrated long-term safety profile through Week 52

Adverse reactions occurring in ≥2% of patients (and greater than placebo) up to Week 521
DUPIXENT
300 mg Q2W + OCSa 
(n=53)
%		 PLACEBO + OCSa 
(n=53)
%
Arthralgia
9 6
Conjunctivitis
8 0
Vision blurred
8 0
Herpes viral infectionsb
6 0
Keratitis
4 0
  • A case of acute generalized exanthematous pustulosis (AGEP) was reported in 1 subject with BP treated with DUPIXENT compared with 0 subjects in the placebo group1
  • At the time of safety analysis, 87 subjects had completed Week 36 and 65 subjects had completed Week 521

aAll subjects received DUPIXENT or placebo in combination with a tapering course of oral corticosteroids (OCS).

bHerpes viral infections include herpes simplex and herpes zoster.

Other attributes and considerations

NOT AN
IMMUNOSUPPRESSANT
OR A STEROID1
NO KNOWN DRUG-TO-DRUG
INTERACTIONS1

Not metabolized through the liver or excreted through the kidneys

NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING1

according to the Prescribing Information

AT-HOME
SELF-ADMINISTRATION1

Train patients and/or caregivers on proper administration prior to use

NO BOXED WARNING1

Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

Thinking about prescribing DUPIXENT?

Find the information you need to get started.

dosage and administration

BP, bullous pemphigoid; Q2W, once every 2 weeks.